In the present work, we described two porphyrazines with several benefits over previously published compounds: a red shift of absorption and emission maxima that is important for future in vivo application; higher PDT activity against cancer cells and large photodynamic index; and low toxicity against neuronal cells [25], which allows pz IV and especially pz II application for treatment of gliomas. The gene discussed is PROZ; the disease is cancer.